BeOne Medicines AG (49BA.F)
Develops cancer medicines including blood cancer treatments and immunotherapies for patients worldwide.
284.00+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+12.7%
The outlook
BeOne Medicines trades at 284 with limited analyst coverage. The stock sits well above its 50- and 200-day moving averages and sits roughly two-thirds of the way through its 52-week range, suggesting middling momentum. The trailing P/E of 73 reflects a premium valuation typical of early-stage biotech firms.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range62% of the way from its 52-week low to high
Market cap
$29.47B
52-wk high
322.00
52-wk low
222.00
50-day avg
251.04
200-day avg
266.77
Trailing P/E
73.0